Allison Shuke
Medical · New Paris, PANPI 1790415487
Payments from drug & device makers
Across 337 payments — averaging $16.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$961
- Pfizer$671
- Novo Nordisk$471
- AstraZeneca$368
- Lilly USA, LLC$357
- Boston Scientific$215
- plus $3K from 41 others
What the payments were for
- Food & beverage$5,62698%
- Education$952%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$131
- BREZTRI$131
- FARXIGA$131
- WATCHMAN FLX$108
How this compares
$5,721 in reported general payments places this provider in the 90th percentile of 2,594 medical providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 91 | $78,616 |
| MounjaroTirzepatide | 50 | $49,965 |
| EliquisApixaban | 49 | $43,102 |
| OzempicSemaglutide | 36 | $32,359 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $25,609 |
| XareltoRivaroxaban | 30 | $19,415 |
| FarxigaDapagliflozin Propanediol | 32 | $18,883 |
| EntrestoSacubitril/Valsartan | 13 | $11,627 |
| Potassium Chloride | 88 | $11,505 |
| TrulicityDulaglutide | 12 | $10,519 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $10,140 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $9,894 |
| Repatha SyringeEvolocumab | 11 | $8,889 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 48 | $7,975 |
| TradjentaLinagliptin | 11 | $7,052 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $98 | $85,668102 claims |
| Lilly USA, LLCMounjaro, Trulicity | $357 | $60,48362 claims |
| PfizerEliquis | $671 | $43,10249 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $211 | $35,74951 claims |
| Novo NordiskOzempic | $471 | $32,35936 claims |
| AstraZenecaFarxiga | $368 | $18,88332 claims |
| NovartisEntresto | $74 | $11,62713 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $43 | $4,81511 claims |
| AbbVieSynthroid | $961 | $1,33016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,594 medical providers in Pennsylvania.
Other medical in New Paris
- Jacqueline KernaghanSpringfield$427K
- Drew SodaNew Hope$220K
- Angela KapalkoPhiladelphia$123K
- Linda PerryPhiladelphia$123K
- Cory DavidsonErie$119K
- Shelley SassamanTamaqua$90K
- Meghan HoffnerBethlehem$86K
- Thomas IacovoniDanville$72K
- Scott CoxWynnewood$66K
- Sarah SmithPhiladelphia$65K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.